Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting

Rhea-AI Summary

Cogent Biosciences (Nasdaq: COGT) announced multiple posters presenting bezuclastinib SUMMIT trial data in nonadvanced systemic mastocytosis at the 2026 AAAAI Annual Meeting in Philadelphia, Feb 27–Mar 2, 2026.

Posters are scheduled Feb 28, 2026, 9:45–10:45am ET in Convention Center, Ground Level, Hall A, covering expanded results, biomarkers, symptom burden, patient experience, subgroup analyses, and correlations with objective measures. The company disclosed it submitted an NDA for bezuclastinib in NonAdvSM in Dec 2025 and holds Breakthrough Therapy Designation.

Key Figures

AAAAI meeting dates: February 27–March 2, 2026 Poster session time: February 28, 2026 – 9:45am–10:45am ET Poster number: 519 +5 more

8 metrics

AAAAI meeting dates February 27–March 2, 2026 2026 American Academy of Allergy Asthma & Immunology Annual Meeting

Poster session time February 28, 2026 – 9:45am–10:45am ET Session time for multiple SUMMIT trial posters

Poster number 519 Expanded Results from Phase 2 SUMMIT Trial

Poster number 520 Bone formation marker changes exploratory analysis in SUMMIT

Poster number 510 Patient experience of living with NonAdvSM

Poster number 523 Improvement of symptom burden in SUMMIT

Poster number 532 Symptom improvement vs objective disease measures

Poster number 521 Results in SUMMIT subgroups with unmet need

Market Reality Check

Price: $37.95 Vol: Volume 1,199,666 is below...

low vol

$37.95 Last Close

Volume Volume 1,199,666 is below 20-day average of 2,087,223, suggesting a modest reaction to the update. low

Technical Shares at $37.95 are trading above the 200-day MA of $18.95, reflecting a pre-existing uptrend ahead of the poster disclosures.

Peers on Argus

COGT gained 2.35% while key biotech peers like CLDX (+4.51%) and IMCR (+4.00%) a...

COGT gained 2.35% while key biotech peers like CLDX (+4.51%) and IMCR (+4.00%) also advanced, but no names appeared in the momentum scanner, supporting a stock-specific move tied to SUMMIT poster visibility.

Historical Context

5 past events · Latest: Jan 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 26	Breakthrough designation	Positive	+3.2%	FDA Breakthrough Therapy Designation for bezuclastinib+sunitinib in GIST.
Jan 20	NDA/RTOR update	Positive	+2.5%	FDA agreement to accept PEAK NDA under Real-Time Oncology Review.
Jan 12	2026 milestones	Positive	-1.7%	Outlined 2026 NDA timelines, trial presentations, and commercial launch targets.
Jan 06	Conference presentation	Positive	+1.5%	Planned presentation at J.P. Morgan Healthcare Conference with webcast access.
Dec 30	NDA submission	Positive	-2.1%	Filed NDA for bezuclastinib in NonAdvanced SM based on positive SUMMIT data.

Pattern Detected

Recent clinical and regulatory milestones for bezuclastinib generally saw positive stock reactions, though pivotal NDA steps in NonAdvSM triggered occasional profit-taking.

Recent Company History

Over the last few months, Cogent highlighted multiple milestones for bezuclastinib, including an NDA submission for NonAdvSM on Dec 30, 2025 and FDA Breakthrough Therapy Designation in GIST with strong PEAK data on Jan 26, 2026. Additional updates covered RTOR-based NDA plans and a 2026 milestones roadmap, including multiple NDA submissions and anticipated launches. Today’s SUMMIT poster announcements at AAAAI extend this sequence by adding more detailed NonAdvSM data to support the previously filed NDA and broader 2026 launch narrative.

Market Pulse Summary

This announcement highlights multiple SUMMIT trial posters at AAAAI 2026, expanding on bezuclastinib...

Analysis

This announcement highlights multiple SUMMIT trial posters at AAAAI 2026, expanding on bezuclastinib data in NonAdvSM across efficacy, symptom burden, bone markers, patient experience, and high‑need subgroups. It builds on the NDA submission disclosed in December 2025 and prior Breakthrough Therapy Designation. Investors may watch for how these detailed data support the overall benefit–risk profile in NonAdvSM and complement earlier pivotal readouts used for the NDA.

Key Terms

new drug application, breakthrough therapy designation, phase 2, pivotal trial

4 terms

new drug application regulatory

"Cogent announced that the company submitted its New Drug Application for bezuclastinib"

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

breakthrough therapy designation regulatory

"follows the Breakthrough Therapy Designation for bezuclastinib in patients with SSM"

A breakthrough therapy designation is a regulatory fast-track given to a drug or treatment that shows early signs of providing a major improvement over existing options for a serious condition. Think of it as a VIP lane that can speed up development and more intensive guidance from regulators, which matters to investors because it can shorten time to market, reduce development risk and potentially increase a company’s value — though it does not guarantee approval.

phase 2 medical

"Expanded Results from the Phase 2 Summit Trial: Bezuclastinib in Adults"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

pivotal trial medical

"based on positive clinical data from the SUMMIT pivotal trial and follows"

A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.

AI-generated analysis. Not financial advice.

WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced multiple upcoming posters highlighting bezuclastinib results from the SUMMIT trial in NonAdvanced Systemic Mastocytosis (NonAdvSM) patients at the 2026 American Academy of Allergy Asthma & Immunology Annual Meeting (AAAAI) being held in Philadelphia, PA, February 27-March 2, 2026.

In December 2025, Cogent announced that the company submitted its New Drug Application for bezuclastinib in NonAdvSM to the U.S. Food and Drug Administration. The submission is based on positive clinical data from the SUMMIT pivotal trial and follows the Breakthrough Therapy Designation for bezuclastinib in patients with SSM and patients with NonAdvSM who have received prior avapritinib.

AAAAI Poster Details:

Poster Presentation Title: Expanded Results from the Phase 2 Summit Trial: Bezuclastinib in Adults with Nonadvanced Systemic Mastocytosis
Session Date and Time: February 28, 2026 – 9:45am – 10:45am ET
Poster Number: 519
Location: Convention Center, Ground Level, Hall A

Poster Presentation Title: Evaluation of Bone Formation Marker Changes in Summit, a Trial Assessing Bezuclastinib in Adults with Nonadvanced Systemic Mastocytosis: An Exploratory Analysis
Session Date and Time: February 28, 2026 – 9:45am – 10:45am ET
Poster Number: 520
Location: Convention Center, Ground Level, Hall A

Poster Presentation Title: Results From the Phase 2 Summit Trial of Bezuclastinib in Adults with Nonadvanced Systemic Mastocytosis: Patient Experience of Living with NonAdvSM
Session Date and Time: February 28, 2026 – 9:45am – 10:45am ET
Poster Number: 510
Location: Convention Center, Ground Level, Hall A

Poster Presentation Title: Improvement of Symptom Burden in Summit: Bezuclastinib in Adults with Nonadvanced Systemic Mastocytosis
Session Date and Time: February 28, 2026 – 9:45am – 10:45am ET
Poster Number: 523
Location: Convention Center, Ground Level, Hall A

Poster Presentation Title: Results from the Summit Pivotal Trial: Symptom improvement correlates with reductions in objective measures of disease in adults with nonadvanced systemic mastocytosis
Session Date and Time: February 28, 2026 – 9:45am – 10:45am ET
Poster Number: 532
Location: Convention Center, Ground Level, Hall A

Poster Presentation Title: Results in Subgroups with Unmet Need in the Summit Trial: Bezuclastinib in Adults with Nonadvanced Systemic Mastocytosis
Session Date and Time: February 28, 2026 – 9:45am – 10:45am ET
Poster Number: 521
Location: Convention Center, Ground Level, Hall A

About Cogent Biosciences, Inc.
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2/3 inhibitor. In addition, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα, KRAS and JAK2. Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: X (formerly known as Twitter) and LinkedIn. Information that may be important to investors will be routinely posted on our website and X.

Contact:
Christi Waarich
Senior Director, Investor Relations
christi.waarich@cogentbio.com
617-830-1653

FAQ

What will Cogent Biosciences (COGT) present about bezuclastinib at AAAAI 2026?

Cogent will present multiple SUMMIT trial posters on Feb 28, 2026, focused on efficacy, symptoms, biomarkers, and patient experience. According to Cogent Biosciences, the posters include expanded Phase 2 and pivotal-trial analyses and subgroup results relevant to NonAdvSM patients.

When and where are the COGT SUMMIT posters scheduled at the 2026 AAAAI meeting?

All Cogent SUMMIT posters are scheduled Feb 28, 2026, 9:45–10:45am ET in Convention Center Ground Level, Hall A. According to Cogent Biosciences, poster numbers include 510, 519, 520, 521, 523, and 532.

Has Cogent (COGT) submitted regulatory filings for bezuclastinib in NonAdvSM?

Yes. According to Cogent Biosciences, the company submitted a New Drug Application for bezuclastinib in NonAdvSM in December 2025. The submission is based on positive clinical data from the SUMMIT pivotal trial.

Which SUMMIT trial topics did Cogent include in its AAAAI 2026 posters for COGT?

The posters cover expanded Phase 2 and pivotal results, bone formation marker changes, symptom-burden improvement, patient experience, subgroup analyses, and symptom-objective measure correlations. According to Cogent Biosciences, these topics derive from SUMMIT trial data in NonAdvSM.

What investor implications does the AAAAI poster program have for Cogent Biosciences (COGT)?

The poster program publicly details SUMMIT clinical findings and may inform clinician and regulator assessment ahead of review processes. According to Cogent Biosciences, the presentations accompany an NDA submitted in Dec 2025 and Breakthrough Therapy designations for bezuclastinib.